Separately, I'm not sure why Dr. Perry said that the case of a drug improving or benefiting patients through a long period has never been witnessed before when you have shown results from the Flurizipan study in detailed charts, clearly showing about a good 18% showing retained improvement at the 12 month interval.
I cringed when I heard him say that. I certainly hope everyone hear checks and verifies every link I have posted for themselves. I’m definitely not an expert by any stretch of the imagination. I’m trying to get answers just like everyone here. I share what I find, that’s all. I could be misinterpreting the meaning of those graphs. Decide for yourselves, that’s why I try to always add links. I’m just some dude posting on a message board with no professional qualifications outside of what Google tells me.
I actually decided earlier today that I would try and write Dr.Perry myself to provide him with my DD that I posted here. I would love to know what he thinks about it’s validity. If he replies I’ll definitely share it if he ok’s it.
I can only comment that I believe I have shown another instance where a PHD who writes for (Alzheimer’s news today) seems to have been befuddled by Anavex’s graphical data as well. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132109424
Here are the graphs (on Slide 26.)
Were that sources statements accurate? http://www.anavex.com/my_uploads/ANAVEX2-73-PKPD-Phase-2a-2017.pdf
How did I know that some patients actually had declined? Some did decline didn’t they?
If I’m reading the graphs correctly only 7 of 27/28 increased and every other patient’s scores declined. Do you agree with that statement?